Podcasts about chronic myeloid leukemia

Join host Talaya Dendy on Navigating Cancer TOGETHER as she welcomes Tim Sohn, an 18-year chronic myeloid leukemia (CML) survivor. Tim shares his personal journey, the importance of community building, his involvement in the #SpeakUpCML campaign, and the impact of living with an invisible illness. Don't miss this inspiring conversation filled with hope, resilience, and valuable insights for cancer patients, survivors, and supporters.✨Highlights from the show:02:33 Tim's Cancer Journey and Community Building12:11 Challenges and Mental Health17:19 Support Systems and Resources32:54 Showing Up: Perspectives on CancerTranscript: https://bit.ly/podscript156-2

Prof Andreas Hochhaus from Jena University Hospital in Germany, Dr B Douglas Smith from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins in Baltimore, Maryland, and moderator Dr Michael J Mauro from Memorial Sloan Kettering Cancer Center in New York, New York, discuss recent updates on available and novel treatment strategies for chronic myeloid leukemia. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHCML24).

In this week's episode we'll learn more about the ASCEND study, which investigated first-line asciminib in chronic phase chronic myeloid leukemia; a new risk score for myeloid neoplasm transformation in patients with clonal cytopenia of undetermined significance; and use of RHD genotyped D-positive blood transfusions in patients with sickle cell and unexpected anti-D antibodies.Featured ArticlesAsciminib Monotherapy as Frontline Treatment of Chronic Phase Chronic Myeloid Leukaemia - Results from the ASCEND StudyRisk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence Genotyped RhD+ red cells for D-positive patients with sickle cell disease with conventional RHD and unexpected anti-D 

Featuring perspectives from Dr Bhavana (Tina) Bhatnagar, Dr Amanda Blackmon, Dr Jorge Cortes, Dr Michael J Mauro and Dr Neil P Shah, including the following topics: Recently presented data affecting the treatment of newly diagnosed chronic myeloid leukemia (CML) (0:00) Case: A man in his mid 40s with newly diagnosed CML with tyrosine kinase inhibitor (TKI) tolerability issues but a good response (24:51) Case: A woman in her mid 80s with chronic-phase CML (CP-CML) with translocation (9;22) (40:26) Case: A woman in her mid 80s with CP-CML and notable comorbidities (43:12) Case: A woman in her early 50s with CP-CML intolerant to dasatinib (51:22) Case: A woman in her late 50s with CP-CML and TKI withdrawal syndrome (1:01:22) Case: A woman in her mid 50s with accelerated-phase CML (1:08:22) Case: A woman in her early 70s with CP-CML and a suboptimal response to second-line TKI (1:17:00) Case: A man in his mid 30s with CP-CML and a complex variant Ph-positive translocation (1:23:24) Case: A man in his mid 30s with CP-CML and a T315I mutation (1:28:55) CME information and select publications  

Practical Perspectives: Current Management of Chronic Myeloid Leukemia | Faculty Presentation — Jorge Cortes, MD  CME information and select publications

Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia.

Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/CML2024/CaseRoundtable).

Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, as they dive into the world of Chronic Myeloid Leukemia (CML) with world-renowned hematologist Dr. Jorge Cortes from the Georgia Cancer Center. In this episode, they discuss the current standard of care treatment options for CML, including risk stratification, monitoring, treatment algorithms, and side effects of first, second, and third-generation TKIs. Dr. Cortes provides valuable insights on when to consider treatment holidays, switching therapies, and the potential benefits of upcoming treatments like asciminib. The discussion also covers the importance of deep molecular responses, the role of bone marrow biopsies, and the decision-making process for patients in accelerated phase CML. Tune in to gain a comprehensive understanding of managing CML patients in the community setting and stay updated on the latest advancements in hematology and oncology. Don't miss out on this informative episode with the Oncology Brothers podcast!   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Primary results from ASC4FIRST trial, the first study in chronic myeloid leukemia comparing current standard-of-care frontline tyrosine kinase inhibitors with the novel agent asciminib in newly diagnosed patients, were reported at the 2024 ASCO Annual Meeting. First author Timothy Hughes MD, Consultant Hematologist with the Royal Adelaide Hospital, the South Australian Health and Medical Research Institute, and the University of Adelaide in Australia, reported higher efficacy in terms of major molecular responses and lower toxicity with asciminib. After his talk in Chicago, he met up with Oncology Times reporter, Peter Goodwin.

Josh “Juice” Little – Essington.  In his early 20's, Josh was diagnosed and defeated Hodgkin's Lymphoma. Three cancer-free years went by, but there were always intrusive thoughts that it could return. Sadly, in October of last year, that did happen, and it came back in the form of Chronic Myeloid Leukemia. Thanks to advancements and specialized treatment that can be provided in this area surrounding Delco, Josh is managing the diagnosis with some cutting-edge therapy, and the prognosis is excellent. Josh is an icon of South Delco, from one of the most entertaining families in the County, and has helped with several Delco Days in the past. It is an honor to make him one of the Benefactors of this year's installment. www.DelcoLive.com

When Tim Sohn spotted some unusual bruises on one of his legs, he sought medical attention.  This led to hospitalization and a subsequent diagnosis of a form of blood cancer, chronic myeloid leukemia.  With the aid of two types of oral chemotherapy, Tim survived.  His experience inspired him to help others diagnosed with cancer, in the form of a book and a live podcast.  This is his story.

Serghei Tvetcov is living with Leukemia. He was diagnosed with cancer in September 2022. He was racing with his Wildlife Generation Pro Cycling Team in the Tour of Romania when he got the results. He says he knew something wasn't right. Tvetcov simply couldn't put out the numbers he was used to doing. So he went and got tested. The test revealed he was living with Chronic Myeloid Leukemia. He says the result were a kick in the head. For treatment he takes chemo directed pills twice a day. Every three months he has a genetic test that shows him his response to the meds. He says it's a cancer that's not curable rather it's something he'll live with for the rest of his life. Tvetcov says he plans to race in 2024. His plans include racing gravel and spreading a message of survival. He wants folks who have the same disease to know you can live and thrive while living with Chronic Myeloid Leukemia. Also in this episode we also touch on his start in cycling, coming to America, racing in Italy, and France. And racing for the famous Gianni Savio. 

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Shelley: Hi Dr. Cabral. I love you and your work. Thank you. My question is about my daughter who was diagnosed with JRA at the age of 13. She has been on various meds and is currently on Humira to control her symptoms. She has had a positive ANA test and a Centromere B ab of 1.4 which is high. Her doctor is concerned about CREST among other things. She also has had Myastenia Gravis. All serious auto immune diseases. She tries to be gluten free and careful with her diet but as an 18 year old going to college, I am concerned. What advice might you have to get control of this auto immune nightmare? Thank you for all you do.   Lindsey: hi dr. cabral! thank you for this podcast and all of your knowledge. i have 2 questions for you — 1.i run a body fever most nights. i notice it significantly when i lay down to go to sleep and my partner says i'm literally radiating heat. i suspect my body is trying to fight off something - what do you suggest as a first step in finding the root cause?2. my heart races/gets faster after meals (whether it be healthy or unhealthy food). can you help?thank you Tiffany: Ive listened to your podcast for 10 yrs & am grateful for your passion your knowledge & helping people. Question: An older friend of mine had to have emergency surgery to remove a non cancerous infected mass from her bowl & has been on a constant antibiotic drip for 2 wks. The I.V. was just removed & she is home w/a drainage bag still attached outside of her body to help rid the infection. When I found this out, I immediately ordered for her the Clean Gut Pros, Saccharomysis Boulardii & a 7 day detox. I was also able to talk her into The Big 5, to get the root cause. She then mentioned she also has Chronic Myeloid Leukemia. I tried to research your podcasts for info on this with no luck. Lab results will soon reveal but want any advice on CML to be in your podcasts. Much appreciated! Mandy: Hi doctor Cabral, I've been following your work, and listening to your podcast for years, and it has truly changed by health for better, so I'm eternally grateful. I have a question about my parents: they are both in their mid-70s and I want to keep them as healthy as possible. What are some essential supplements that they should definitely be using? They are not on anything now. They both eat pretty healthy and walk around 20K steps a day. Thanks so much for your advice! Erika: Breast question (I have a dr appointment next week and i know it will be weeks until you get to this but that's okay, would love your opinion)….we did a lot of hiking in the mountains 2 weeks ago and i had a backpack on. After the 5th day, at the end of the day i noticed one breast on the underside looked bruised or like the veins were widened and very visible. I've never had this before…. The blue color will be very light in the morning but after exercising it's back darker again. And only on the underside of the boob.Any idea what is happening?   Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/2816 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Nourishing your body after a cancer diagnosis can seem like an impossible task when your mind is focused on survival.… The post Fueling Hope: Nutrition Insights for Chronic Myeloid Leukemia (CML) appeared first on The Bloodline with LLS.

Nourishing your body after a cancer diagnosis can seem like an impossible task when your mind is focused on survival.… The post Fueling Hope: Nutrition Insights for Chronic Myeloid Leukemia (CML) first appeared on The Bloodline with LLS.

Are you currently facing adversity? How are you coping while navigating life's challenges?   In this week's episode, we have an interview with Frank McKinney, who successfully fought and overcame Chronic Myeloid Leukemia. He is now two years cancer-free and has written a book about his experience and how he conquered one of the greatest adversities in his life.   After listening to this episode, you will definitely want to buy the book as it not only offers valuable insights but also can help an entire village in Haiti.   Key takeaways from the episode:   Adversity can make you feel dead inside, so take risks and do something that makes you feel most alive. Your adversity has a purpose. Do not hold onto the past or difficult times because tomorrow is a new day. Do not become a victim of "Stockholm Syndrome" when facing adversity. Acknowledge it and do not let it consume you.

Join us as we hear two different perspectives from people living with chronic myeloid leukemia (CML); Tim Sohn, a 16-year… The post Perspectives on Quality of Life: Chronic Myeloid Leukemia (CML) first appeared on The Bloodline with LLS.

Join us as we hear two different perspectives from people living with chronic myeloid leukemia (CML); Tim Sohn, a 16-year… The post Perspectives on Quality of Life: Chronic Myeloid Leukemia (CML) appeared first on The Bloodline with LLS.

Alexa Score is a professional wakeboarder, TV host, speaker, and cancer survivor. Born and raised in small town Spicer, Minnesota, she hails from humble Midwestern roots, and now splits time between  Orlando, Florida and Minneapolis, Minnesota.She has represented numerous global brands including Liquid Force, Hard Rock Cafe, LifeProof, SPY Optic, Body Glove, and others. She has appeared in print and video ads across the globe and has a plethora of experience in the TV and film industries, including being a TV personality on networks such as MTV, ESPN, and Travel Channel, and appearing in the SyFy movie: Two Headed Shark Attack. She's currently a TV personality for the Minnesota Vikings, cohost of Made for the Outdoors (Sportsman Channel and Fox Sports Networks), cohost of Destination Polaris (Fox Sports Networks), and a member of The CW Twin Cities on-air crew. Alexa was diagnosed with Chronic Myeloid Leukemia at age sixteen and has been living with cancer for the past thirteen years. Her journey is far from over as she continues to battle her disease and its side effects. She uses her platform to raise money and awareness for multiple charities including: The Leukemia & Lymphoma Society, BeTheMatch.org, and others. Despite dealing with the constant side affects of cancer and treatment, Alexa has made it a priority to live an active, energetic, and healthy lifestyle.Alexa is a life force and inspiration to others, it was such an honor to have her on the show!  Listen now on A Juicy Pear Podcast.  If your feeling lead, you can Buy Me A Coffee on http://www.ajuicypearpodcast.comSupport the show

Join us as we speak to Dr. Richard Larson and Dr. Anand Patel from University of Chicago Medicine about chronic… The post Hopeful Advancements for Chronic Myeloid Leukemia (CML) appeared first on The Bloodline with LLS.

Join us as we speak to Dr. Richard Larson and Dr. Anand Patel from University of Chicago Medicine about chronic… The post Hopeful Advancements for Chronic Myeloid Leukemia (CML) first appeared on The Bloodline with LLS.

Ehab Atallah, MD, Medical College of Wisconsin, Milwaukee, WI Recorded on January 24, 2023 In this episode, Dr. Ken Miller sits down with Dr. Ehab Atallah, from the Medical College of Wisconsin, to discuss chronic myeloid leukemia (CML) including the development of tyrosine kinase inhibitors (TKIs), challenges with adherence to treatment, side effect management, and long-term and late effects, including cardiac toxicities. Dr. Atallah describes the work of the H. Jean Khoury Cure CML Consortium, shares his insights in to transitioning patients off TKIs, experience with his patients living with measurable residual disease, and excitement about the future of CML therapy. Learn more by tuning in today!

Dr Bill Nelson speaks with Lindsey Ledwin, a patient diagnosed with Chronic Myeloid Leukemia in 2018, and Dr Tania Jain one of her oncologists, about her cancer journey and advocacy for other patients being treated at the Johns Hopkins Kimmel Cancer Center.

Today we are  joined by Becky Dame, currently an Information Specialist at The Leukemia & Lymphoma Society, RN and Survivor. As Peggy says in the podcast, callers who end up talking to Becky must feel like they've hit the information jackpot.  Becky is a chronic myeloid leukemia (CML) survivor who went on to become a cancer care nurse, before she transitioned to her current role.  Today, we tap into her wealth of personal and professional experience.Becky was diagnosed as a college student in 1991, and received her first bone marrow transplant in 1992.  At this time, she felt called to be a nurse and changed from a music major to nursing school, marrying her husband on the day she graduated.  For 18 years, she went through cycles of relapse, always on the lookout for the newest treatments for her disease.  Then, in 2010, she received a matched unrelated donor (MUD) transplant, and was able to break that cycle.  Today, however, Becky battles Graft vs. Host Disease (GVHD).In 2017, she joined The Leukemia & Lymphoma Society, where she says it's her goal to share her "pearls" of wisdom with patients, caregivers, and anyone else that she can find commonalities with. Becky speaks to the importance of finding a primary caregiver --transplant is not a journey you can go at alone.  Also, plan to be out of work for at least a year - and we cover some resources available to patients. There are also practical tips in today's podcast, such as why wearing a button-up shirt to the hospital can be a clutch move.Finally, Becky reflects on her journey, saying there's nothing she would change, feeling like everything happens for a reason, and now she's here to help others.The Leukemia & Lymphoma Society for One-on-One Supporthttps://www.lls.org/patient-support, 1-800-955-4572Other ResourcesNational Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page:  https://www.facebook.com/nbmtLINKnbmtLINK YouTube Page can be found by clicking here.Thank you to this season's sponsors:The Leukemia & Lymphoma Society, www.lls.orgSanofi: https://www.sanofi.com/  

This week's episode will be focusing on Chronic Myeloid Leukemia or CML for health care providers. We will go all the important details on the genetics of CML, diagnosis and treatment algorithms.

In this episode, we review the high-yield topic of Chronic Myeloid Leukemia (CML) from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://anchor.fm/medbulletsstep1/message

To acknowledge the Philadelphia Chromosome translocation t(9;22) in chronic myeloid leukemia (CML), every September 22 (9/22) is World CML Day. Today's podcast episode looks at this topic through different lenses. First, two members of the Lancet Haematology's committee on adverse events—Jan Geissler, co-founder of the CML Advocates Network, and Gita Thanarajasingam, MD, the committee chair and a hematologist at the Mayo Clinic—discuss how side effects are reported and analyzed and how the committee intends to change that. Geissler also talks about how his experience as a patient with CML led him to become and expert advocate. Additional reading:Geissler J, Huber S. Improving outcomes through patient-generated evidence-the next step in patient advocacy. Lancet Haematol. 2022 Jun;9(6):e399-e400. Thanarajasingam G, et al. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2022 May;9(5):e374-e384Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017 Jul 11;318(2):197-198. 

Today Gleevec is an incredibly common cancer treatment.  But like every drug on the market, it went through clinical trials more than two decades ago.  Our guest today, Mel Mann, was the second person to receive the drug, back in 1998. And it saved his life.Mel was diagnosed with chronic myeloid leukemia, (CML) in 1995 and was given three years to live.  At the time, a bone marrow transplant was the only option. The registry had far less people on it than today, particularly people of color.  At the time, only 1% of black patients could find a match.  So Mel, an Army Major at the time, did what he did best--with boots on the ground, he started organizing bone marrow drives - everywhere. And he enlisted his incredible friends to do the same.And while Mel didn't find a match, it was a chance meeting at a relative's drive that would change his life forever.  He takes us through the series of events that introduced him to a clinical trial for Gleevec, and just in time.  He ended up not needing a transplant. Mel is proud to say he not only got to see his daughter, five years-old when Mel was diagnosed, grow up but she has also become a doctor. We spend some time with Mel talking about clinical trials, and how important, even life-saving they can be.  As a patient, you truly need to be your own best advocate and Mel will show you the way.More:US Clinical Trials Website: https://clinicaltrials.gov/National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page:  https://www.facebook.com/nbmtLINKnbmtLINK YouTube Page can be found by clicking here.Thank you to this season's sponsors:Omeros Corporation: https://www.omeros.com/Incyte: https://www.incyte.com/

Maggie and I go way back (like... to middle school) and we've only reconnected after all these years due to having something very personal in common... cancer as a young adult.  Her story is UN-BE-LIEVE-ABLE. She tells us about being diagnosed so young, her battle with Chronic Myeloid Leukemia, surviving  a bone marrow transplant, getting a new birthday and so much more.SUPPORT THE SHOWPODCAST/CANCER MERCH: Visit facingfearwithsara.com/merchCATCH UP ON MY CANCER JOURNEY: facingfearwithsara.com/episodesCONNECT With the guest, @hardintomaggieSubscribe to the monthly newsletter at facingfearwithsara.comInstagram - @facingfearwithsara, @saramcinerneyhauckTikTok - @facingfearwithsaraFacebook - @facingfearwithsaraWebsite - facingfearwithsara.comYouTube - Sara McInerney HauckEmail - hello@facingfearwithsara.com Support the show

Featuring perspectives from Dr Daniel DeAngelo, including the following topics: Introduction: Perspectives on chronic myeloid leukemia (CML) (0:00) Asciminib — ASC4FIRST study (8:33) Case: A woman in her early 60s with a PMH of Stage IA hormone receptor-positive breast cancer on adjuvant tamoxifen with newly diagnosed CML — Michael R Grunwald, MD (22:38) Case: A man in his mid 40s with low-risk CML who achieves MR4 on imatinib but loses molecular response 3 months after discontinuing therapy — Shams Bufalino, MD (27:23) Case: A man in his early 40s with CML on dasatinib who does not achieve treatment milestone (MR3) at 18 months but does at 24 months — Dr Grunwald (33:19) Case: A man in his early 80s with CML who initially receives imatinib followed by nilotinib develops CHF and has a BCR-ABL of 0.8% (IS) — Namrata I Peswani, MD (37:33) Case: A woman in her late 20s with CML that is resistant to multiple TKIs and therapy compliance concerns — Minesh Dinubhai Patel, MD (40:44) Case: A woman in her early 40s who initially receives dasatinib for chronic-phase CML with a good response but then develops lymphoid blast crisis — Dr Grunwald (52:17) Case: A woman in her mid 70s with CML who achieves MMR on nilotinib but then develops peripheral arterial occlusion after 9 years on therapy — Dr Grunwald (58:10) CME information and select publications

Featuring a discussion on the treatment of chronic myeloid leukemia with Dr Daniel DeAngelo, moderated by Dr Neil Love.

Featuring perspectives from Dr Jorge Cortes, including the following topics: Introduction: Journal Club with Dr Cortes (0:00) Case: A man in his early 40s with chronic myeloid leukemia (CML) and osteopenia after long-term imatinib therapy — Rajalaxmi McKenna, MD (15:00) Case: A man in his early 60s with chronic phase CML (CP-CML) and continued detectable BCR-ABL transcript on bosutinib — Bruce Bank, MD (23:55) Case: A man in his early 70s with CP-CML and notable toxicities from several BCR-ABL tyrosine kinase inhibitors (TKIs) — Gigi Chen, MD (27:37) Case: A woman in her late 40s with CML in complete molecular response for more than 3 years with nilotinib — Michael R Grunwald, MD (36:05) Case: A woman in her mid 60s with CP-CML and negative BCR-ABL mutational analyses who experiences lack of disease response to several BCR-ABL TKIs — Shams Bufalino, MD (43:27) Case: A man in his early 40s with CP-CML who is found to have a T315I mutation — Dr Grunwald (44:45) Appendix of Key Recent Data Sets (53:26) CME information and select publications

Featuring a discussion on the treatment of chronic myeloid leukemia with Dr Jorge Cortes, moderated by Dr Neil Love.

This podcast follows a short discussion between two young hematologists on a clinical case review of a chronic myeloid leukemia patient called Naomi. In this discussion, the hematologists go through Naomi's case while addressing the management of CML patients in complete molecular response and the requirements for discontinuation of tyrosine kinase treatment in CML patients. This podcast is rendered from QR Case 5 - Chronic Myeloid Leukemia (Naomi) on the EHA Campus. What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to explore more podcasts or clinical cases? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe) 

On the show today I speak with Mel Mann, the longest living person who participated in the clinical trial for Gleevec. When Mel Mann was diagnosed with chronic myeloid leukemia at age 37 in 1995, he was told he had three years to live. But he's here some 26 years later and still going strong. Mel served as a major in the U.S. Army. He kickstarted blood marrow drives all across the country. He started running marathons to raise money for cancer research. He went back to school to become a high school English teacher. And now Mel serves as a cancer advocate and patient activist. He's here to talk about his epic journey.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mel Mann is the World's Longest Living Gleevec (Imatinib) & TKI & Kinase Inhibitor Survivor, 27 Year Terminal Leukemia (CML) Survivor; US Army Retired, Educator, Patient Advocate & Consultant. He Published and appeared in articles such as USA Today, Coping With Cancer Magazine, American Association for Cancer Research (AACR), Cancer Today Magazine etc. He also appeared on numerous television & radio shows as a patient advocate and made a nationwide television commercial for the American Cancer Society (ACS). He has participated on panels such as The Atlantic's People vs Cancer series, Hematology Oncology Pharmacy Association (HOPA), WCG, Patient Power etc. Mel Mann actively collaborates on health equity and ethnic diversity issues with groups such as the American Cancer Society's Cancer Action Network (ACSCAN), Society of Integrative Oncology (SIO) etc. He has participated in numerous nationwide bone marrow drives, including the World's Largest, with 10,675 people joining the marrow registry at a single drive and collaborated in marrow donor recruitment for Be The Match, DKMS Marrow, and the Bill Young Marrow Donor organizations. He is the past National Community Outreach Coordinator of Leukemia & Lymphoma Society's (LLS) Myeloma Link program. He has been a Guest Speaker for Cepheid, Churches, Community Organizations, Leukemia & Lymphoma Society, Cancer Support Groups and the US Army. For being a marrow donor, please visit: http://join.bethematch.org/MelMann.

Dr. Massimo Breccia from the Department of Translational and Precision Medicine at the University of Rome joins us to talk through the top highlights of the chronic myeloid leukemia data from the 2021 American Society of Hematology Conference. Here he gives specific focus to patient unmet needs and later-line therapies for the disease. This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link. All conflicts of interest can be found online. This podcast is intended for medical professionals only. This podcast has been developed through an educational grant from Novartis. The authors were selected by the journal, and the content of the podcast was developed independently by the authors and the journal Editors. The Rapid Service and Open Access Fees were funded by an unrestricted educational grant from Novartis. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.  

In this episode, we review the high-yield topic of Chronic Myeloid Leukemia (CML) from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial

Anne McAuley Lopez with Agency Content Writer Since 2010, Agency Content Writer has provided content for small to medium-sized businesses. Specialties include writing for IT services, real estate, home services, travel, marketing, and legal service clients. Anne McAuley Lopez is a professional content writer. Her work has been featured in Trendsetters, Arizona Republic, Elephant Journal, […] The post Anne McAuley Lopez with Agency Content Writer appeared first on Business RadioX ®.

In episode 7 of "EHA Unplugged", Prof. Shaun McCann describes the clinical and genetic features of chronic myeloid leukemia (CML), discusses the best therapeutic options, and characterizes the changes that occur in the natural history of the disease after the introduction of tyrosine-kinase inhibitors (TKIs). What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the course "EHA Unplugged - Hematological Diseases, HSCT and More". https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe) 

Listen to a soundcast of the October 29, 2021, FDA approval of Scemblix (asciminib) for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with tyrosine kinase inhibitors, and for adult patients in chronic phase with the T315I mutation

Featuring a discussion on the management of chronic myeloid leukemia with Dr Michael Mauro, moderated by Dr Neil Love.

Dr Michael Mauro from the Memorial Sloan Kettering Cancer Center in New York City, New York, discusses the management of chronic myeloid leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCML21).

Featuring an interview with Dr Michael Mauro, including the following topics: Management of chronic myeloid leukemia (CML) (0:00) Case: A woman in her early 40s who received imatinib for 20 years for chronic-phase (CP) CML (37:45) Case: A man in his mid-60s with CP CML and cardiovascular risk factors (39:01) Case: A man in his early 50s with intermediate-risk CP CML 5 years undetectable on asciminib (40:43) CME information and select publications  

This is a story about a bone marrow transplant, a mother's dying wish, a long-held family secret, and how one way to find your sister is by saving her life fourteen years before you met her for the first time. And how all those things came together from six states away in a way that even the people involved still find hard to believe.When Judy Larraga's oncologist told her she needed a bone marrow transplant to be cured of Chronic Myeloid Leukemia in 2004, she consented to the aggressive procedure immediately, despite the risks and challenging treatment course it entailed. And as a Hispanic woman, her chances of finding a suitable donor match to even get the transplant were just 46%. But she never lost hope that there'd be someone out there to help her. Who that “somebody” turned out to be would change Judy's life forever, strengthen her faith in God, and bring a whole new dimension to a family secret her mother revealed on her death bed. It would be 15 years before she knew the rest of the story. 

Chronic myeloid leukemia (CML) is a cancer of the bone marrow and blood. In this episode, Dr. Kareem Jamani provides us with an overview of CML, talks about the advances in treatment options over the years, explores potential barriers to research and imparts messages to those diagnosed with CML. Dr. Jamani is a hematologist at the Tom Baker Cancer Center in Calgary, Alberta.

On this episode of “Matt Michaels' People I Don't Hate” Matt welcomes the promoter of IZW Wrestling (AZ) Greg DeMarco. Greg gives his take on promoting and what it's been like running a promotion with Steve “Navajo Warrior” Islas. We talk the ‘Chairshot' website and podcast. Greg shares his journey of using CrossFit to lose 85lbs. And Greg talks about his diagnosis of Chronic Myeloid Leukemia the same form of leukemia that Roman Reigns has. It an honest telling of a remarkable story but you can only hear it right here on the Vegas Badboyz of Podcasting! And please remember to subscribe, download, listen, review, and share all of the shows from the Vegas Badboyz of Podcasting.

This week, your hosts Steve Lowry and Yvonne Godfrey interview Don Hinkle of Hinkle and Foran (https://www.hinkleforan.com/).    Remember to rate and review GTP in iTunes: Click Here To Rate and Review   Episode Details: Million Dollar Advocates Forum member and accomplished Tallahassee, Florida attorney Donald Hinkle of Hinkle & Foran shares how he held the United States government responsible for the negligence of a U.S. Department of Veterans Affairs doctor who failed to promptly diagnose Vietnam War veteran Ronald Mathis' Chronic Myeloid Leukemia, resulting in his untimely death. In preparation for his annual exam, Ronald underwent routine blood tests, which revealed a white blood cell count twice the normal level. His doctor at the Veterans Affairs facility admitted that he overlooked Ronald's elevated white blood cell count and failed to promptly refer him to a hematologist for what was then a highly treatable condition. Without treatment, Ronald's condition worsened and developed into Acute Myeloblastic Leukemia. He was released to hospice care, where he died less than three weeks later in May 2018. Trial lawyer Donald Hinkle worked to secure economic and noneconomic damages for Ronald's surviving family members recognized under Florida's Wrongful Death Act, including his wife of 52 years, Grace, and his two grandchildren, Autumn and Noah, whom he had adopted and was raising as his own. Ultimately, a federal judge in the U.S. District Court - Northern District of Florida awarded $4,725,961.76 in economic and noneconomic damages to the Mathis family, ruling against the defendant. Click Here to Read/Download the Complete Trial Documents     Guest Bio: Don Hinkle Whether it's representing the injured or working with families who have experienced tragic losses, attorney Don Hinkle's track record of success in undeniable. When not representing clients, Don is often asked to lecture other attorneys regarding how to best handle serious automobile accidents, premises liability and medical malpractice cases. Member of The Million Dollar Advocates Forum for obtained verdicts of more than a million dollars in personal injury, medical malpractice, product liability, automobile crash, premises liability and civil rights cases. When not practicing law, Don enjoys golf, travel, collecting art and his three delightful children. Read Full Bio     Show Sponsors: Legal Technology Services -LegalTechService.com Digital Law Marketing - DigitalLawMarketing.com Harris, Lowry, and Manton - hlmlawfirm.com   Free Resources: Stages Of A Jury Trial - Part 1 Stages Of A Jury Trial - Part 2

In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include:  The macrophage immune checkpoint inhibitor magrolimab in AMLThe STAMP inhibitor asciminib in CML (the ASCEMBL trial)Optimal dosing for the TKI ponatinib in CMLPresenters:Jorge Cortes, MDDirector, Georgia Cancer CenterEminent Scholar, Georgia Research AcademyAugusta, GeorgiaEunice S. Wang, MDProfessor, OncologyChief, Leukemia ServiceDepartment of MedicineRoswell Park Comprehensive Cancer CenterBuffalo, New YorkContent supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.Link to full program and Capsule Summary downloadable slidesets:https://bit.ly/3tyQ9nG 

Brian Boyle is a professional hockey player who is living with Philadelphia-chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). He shares how he coped with the diagnosis and the importance of support along the way. This episode is sponsored by Novartis, and Brian has been compensated by Novartis for participating. Brian’s story is based […]

This episode covers chronic myeloid leukemia!

Rahul Kumar shares his Chronic Myeloid Leukemia journey, his current lifestyle and treatment methods, along with the importance of avoiding stress in our life. ZenOnco.io - Making quality integrative oncology cancer care accessible to all. If you or your loved one has been diagnosed with cancer recently, and need guidance on treatment or have any doubts or queries, please call ZenOnco.io on +91 99 30 70 90 00.

Bravery comes in many forms, and this a story of a brave Chandan Kumar who fought Chronic Myeloid Leukemia with positivity and hope. ZenOnco.io - Making quality integrative oncology cancer care accessible to all. If you or your loved one has been diagnosed with cancer recently, and need guidance on treatment or have any doubts or queries, please call ZenOnco.io on +91 99 30 70 90 00.

*Patrick and Miranda join Greg for his revelation that he has Chronic Myeloid Leukemia--in the most fun way possible. Plus their favorite wrestling thing of 2020.* On this week's edition of the Greg DeMarco Show, the crew has a plan and it ultimately blows up, as Greg shares his Leukemia diagnosis early in the show and they delve into everything surrounding it, how everyone has handled the news, and more! They also dive into 2020 by revealing their favorite "thing" from the world of wrestling in this weird year, and even explore Greg's glass collection? *Follow the Trios Champions on Social Media* * @WrestlngRealist * @TheHashtagMiranda (just not on Twitter!) * @ChairshotGreg * @ChairshotMedia *About the Chairshot Radio Network* Created in 2017, the Chairshot Radio Network presents you with the best in wrestling and wrestling crossover podcasts, including POD is WAR, Women's Wrestling Talk, The #Miranda Show, Badlands’ Wrestling Mount Rushmores, The Outsider’s Edge, DWI Podcast, Bandwagon Nerds, the Greg DeMarco Show, 3 Man Weave, Five Rounds, Turnbuckle Talk, The Reaction and more! You can find these great shows each week at theChairshot.com and through our distribution partners, including podcasting’s most popular platforms. Support this podcast at — https://redcircle.com/chairshot-radio-network/donations Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

Interview with Ehab Atallah, MD, author of Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial

Interview with Ehab Atallah, MD, author of Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial

Al Collings was diagnosed with Chronic Myeloid Leukemia over three years ago. Al talks about learning to live well with a chronic cancer and how it has brought new meaning to his life.

We will be speaking with WWE Superstar, actor, and former professional football player, Joseph Anoai, who many may know as… The post Together in the Fight Against Chronic Myeloid Leukemia (CML): Roman Reigns' Story appeared first on The Bloodline with LLS.

We will be speaking with WWE Superstar, actor, and former professional football player, Joseph Anoai, who many may know as… The post Together in the Fight Against Chronic Myeloid Leukemia (CML): Roman Reigns' Story first appeared on The Bloodline with LLS.

In this episode, Prof. Dr. med Tim Henrik Brümmendorf; Jorge Cortes, MD; and Carlo Gambacorti-Passerini, MD, answer questions focused on the optimal selection and management of tyrosine kinase inhibitor (TKI) therapy in patients with CML, with topics including:Frontline Management of Chronic-Phase CMLSelection of TKI Based on Goal of Treatment-Free RemissionChanging TKIs due to Intolerance: Second-line Therapy and Toxicity ManagementChanging TKIs due to CML Progression: Second-line Therapy and Future OptionsPresenters:Prof. Dr. med Tim Henrik BrümmendorfHeadDepartment of Hematology, Oncology, Hematostaseology, and Stem Cell TransplantationUniversity Hospital Aachen, RWTH AachenAachen, GermanyJorge Cortes, MDDirector, Georgia Cancer CenterEminent Scholar, Georgia Research AcademyAugusta, Georgia, USACarlo Gambacorti-Passerini, MDProfessor, HematologyUniversity Milano BicoccaDirector, HematologySan Gerardo HospitalMonza, Italy Content based on an online CME program supported by an educational grant from Pfizer Inc.Link to full program, including associated downloadable slidesets: https://bit.ly/30P8Uaf

This episode is part of our special series, Looking at Leukemias, and we will be taking a close look at Chronic Myeloid Leukemia (CML). Improved treatment options for CML led to what is now one of the most controllable long-term cancers. While it requires daily medication and monitoring, with proper treatment, it can be managed. Join us as we take a close look at this leukemia and discuss how to live your best life with a chronic cancer. Our guests are Dr. Kendra Sweet from the Moffitt Cancer Center in Tampa, Florida and Diane Krupnick, who has been living with CML for over 5 years.

Alexa Score is a professional wakeboarder, TV host, speaker, and cancer survivor. She’s currently a TV personality for the Minnesota Vikings, Fox Sports and The CW Twin Cities. Alexa was diagnosed with Chronic Myeloid Leukemia at age sixteen and has been living with cancer for the past thirteen years. While still being treated with a daily dose of oral chemotherapy her journey is far from over as she continues to battle her disease and its side effects. She inspires others and uses her platform to raise money and awareness for multiple charities including The Leukemia & Lymphoma Society, BeTheMatch.org, and others. Follow Alexa! @AlexaScore Follow the Show! IG: @afterorangeslices Twitter: @bridgetcase_

At the age of 30, Elle Halliwell was at the top of her game. The Fashion Editor for the Daily Telegraph, regular stints on Channel 9 as the entertainment reporter, and even a weekly show on the Nova radio network, when seemingly out of nowhere, she was diagnosed with Chronic Myeloid Leukemia, turning her world upside down.Then, deep in the midst of coming to terms with the shock of her diagnosis, 48 hours later Elle found out she was pregnant. She was faced with the impossible decision: terminate and begin life saving treatment? Or proceed with the pregnancy and risk her life?Elle shares what it was like to experience the duality of life and death, receiving treatment in the cancer ward and the maternity ward at the same time, her successful career, her beautiful baby boy Tor, the lessons she's learnt along the way, and how she wants to use her story to inspire others.follow Elle: @ellehalliwellconnect with me: @elizabethanilecheck out Elle's book: A Mother's ChoiceAs always, if you enjoyed this chat, I'd absolutely love for you to screenshot it and put it on your stories and tag both Elle and I, your feedback means so much!keep up to date with every Lemonade by hitting subscribe.if you're enjoying this content, please click five stars and leave a review. See acast.com/privacy for privacy and opt-out information.

Hi listeners and welcome to a very special edition of Weekdays with Murph.  As most of you know, a dear friend of the show, Cadence Grace of Runaway Angel, was recently diagnosed with Chronic Myeloid Leukemia and will be undergoing a bone marrow transplant .  We’re joined today by Cadence’s friend and Runaway Angel bandmate, Stacey, to talk about a benefit concert on Sunday in Toronto for Cadence.  The girls of Runaway Angel have always been so incredibly good to me over the years, so I figured it was time to return the favor.  My guest co-host for this one is my buddy Kevin from Kdub Hit Country

The Medikidz take Dean on a journey to the bone marrow to learn more about how blood cells work, symptoms and treatment of chronic myeloid leukemia (CML), possible side effects, and how to find more support.

Brian Boyle is a professional ice hockey player, currently playing for the New Jersey Devils. He is one of 13 children and grew up in Hingham. Brian attended St. Sebastian's School, and then went on to play four years of ice hockey at Boston College. He was drafted to the Los Angeles Kings out of college.Brian's professional hockey career was thrown off course when he was diagnosed with chronic myeloid leukemia in September 2017. He had no symptoms of cancer other than a “steady decline” in energy level. It wasn't until a blood test, conducted in a team physical, that he discovered the cancer.Throughout his treatment, Brian had to take 2 pills a day on an empty stomach. He felt some controllable side effects from his medication, but only missed 10 games throughout the course of his treatment.After his diagnosis, Brian had a different perspective on hockey and life. He realized thatnothing was guaranteed and began to appreciate the smaller moments in life. When he scored his first goal after returning to the Devils, Brian teared up as he celebrated. He says that this was the first time he had ever cried after scoring.Brian is supported by his wife, Lauren, his two-year-old son, infant daughter, and his parents, Artie and Judy.Brian will be throwing out the first pitch tonight.Dr. Stone received his MD in 1981 from Harvard Medical School, his internal medicine residency training at Brigham and Women's Hospital, and his hematology-oncology fellowship at DFCI. He is currently the Director of the Adult Acute Leukemia Program at DFCI, serves on the Medical Oncology Board of the American Board of Internal Medicine, and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and Leukemia Group B.

A budding, fast paced career as a fashion journalist Elle Halliwell seemed to have it all. But in 2016 after a visit to her local doctor, her life quickly turned into a nightmare. Elle was told that she had a rare form of cancer, Chronic Myeloid Leukemia and then just two days later found out that she was also pregnant with her first child. Faced with an almighty decision Elle embarked on an emotional rollercoaster. Today Elle is the mother to happy, healthy little boy Tor and the Author of the incredibly heartfelt book, A Mother's Choice which documents her journey and the decision to forego treatment until after the birth of her child. Welcoming us into her home in Bondi, we chat to this beautiful soul about her unimaginable journey, how she keeps a positive mindset and why health and wellbeing has become her core philosophy.

The ASCO Annual Meeting is the premier educational and scientific event where physicians, researchers, and other health care professionals gather to discuss the latest in cancer care and treatment. In today’s podcast, Cancer.Net Associate Editors answer this question: “What was the most exciting or practice-changing news you heard at the 2017 ASCO Annual Meeting?” Cancer Research News

Today on MedNet21, we're going to discuss Acute and Chronic Myeloid Leukemia.

Interview with Michael Deininger. Prof. And Chief of the Division of Hematology and Hematological Malignances at the University of Utah, Huntsman Cancer Institute, USA. Prof. Deininger discusses the topic 'CLL New Treatments'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Interview with Michael Deininger. Prof. And Chief of the Division of Hematology and Hematological Malignances at the University of Utah, Huntsman Cancer Institute, USA. Prof. Deininger discusses the topic 'CLL New Treatments'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Interview with Francois Mahon. Prof. Of Hematology at Bordeaux University, France. Prof. Mahon discusses the topic 'Can we stop TKIs in patients with CML'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Interview with Francois Mahon. Prof. Of Hematology at Bordeaux University, France. Prof. Mahon discusses the topic 'Can we stop TKIs in patients with CML'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Interview with Prof. Brian Drucker, Professor of Medicine at Oregon Health and Science University, on the following topic, Chronic Myeloid Leukemia (CML): A Success Story from Chromosomes to Effective Therapy. An interview conducted by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Interview with Prof. Brian Drucker, Professor of Medicine at Oregon Health and Science University, on the following topic, Chronic Myeloid Leukemia (CML): A Success Story from Chromosomes to Effective Therapy. An interview conducted by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

ResearchToPractice.com/ASHRounds10 – Rounds with the Investigators – Challenging Cases in Multiple Myeloma, Myelodysplastic Syndrome/Acute Myeloid Leukemia and Chronic Myeloid Leukemia. Featuring case-based discussion with Aristoteles Giagounidis, MD, PhD, Michael J Mauro, MD, Susan M O’Brien, MD, Gail J Roboz, MD, Edward A Stadtmauer, MD and David H Vesole, MD, PhD moderated by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

ResearchToPractice.com/ASHRounds10 – Case-based discussion on Chronic Myeloid Leukemia with Michael J Mauro, MD and Susan M O’Brein, MD moderated by Neil Love, MD. Produced by Research To Practice.

11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews Hagop Kantarjian MD from the MD Anderson Cancer Center in Houston about his latest findings on treating CML in patients who have the T315I mutation. He also discusses the feasibility of patients becoming pregnant while having tyrosine kinase inhibitor (TKI) treatment (among those who have achieved stability for at least two years); and talks about the decreased need for allogeneic transplant.

ONCOLOGY TIMES BROADCAST NEWS WITH THE AUDIO JOURNAL OF ONCOLOGY February 2009 Peter Goodwin interviews more speakers from the 50th American Society of Hematology Annual Meeting, San Francisco, December 6-9, 2008 IN THIS EDITION: Greater Role for Umbilical Cord Blood in Adult Transplants Mary Eapen, Medical College of Wisconsin, Milwaukee COMMENT: Armand Keating, University of Toronto Ex Vivo Expansion Of Cord Blood Derived Progenitor Cells: Patient Transplant Data Colleen Delaney, Fred Hutchinson Cancer Research Center, Seattle COMMENT: Armand Keating Erythropoiesis Stimulating Agents in Cancer Patients: Meta-Analysis Mortality Findings Julia Bohlius, University of Bern ON BEHALF OF: Erythropoiesis Stimulating Agents Individual Patient Data (EPO IPD) Meta-Analysis Collaborative Group COMMENTS: Linda Burns, University of Minnesota, Minneapolis George Canellos, Dana-Farber Cancer Institute, Boston Imatinib: Durable Responses And Survival in Chronic Myeloid Leukemia: 7-Year IRIS Study Results; Can Imatinib Be Stopped? Stephen O'Brien, Newcastle University, England

The carcinoembryonic antigen (CEA) gene family belongs to the immunoglobulin superfamily and can be subdivided into the CEA and pregnancy-specific glycoprotein subgroups. The basic structure of the encoded proteins consists of, in addition to a leader, one IgV-like and 2, 3, or 6 IgC-like domains. These domains are followed by varying COOH-terminal regions responsible for secretion, transmembrane anchoring, or insertion into the membrane by a glycosyl phosphatidylinositol tail. Here we report on the characterization of CGM6, a new member of the CEA gene subgroup, by complementary DNA cloning. The deduced coding region comprises 349 amino acids and consists of a leader, one IgV-like, two IgC-like domains, and a hydrophobic region, which is replaced by a glycosyl phosphatidylinositol moiety in the mature protein. CGM6 transcripts were only found thus far in leukocytes of chronic myeloid leukemia patients, in normal bone marrow, and in marginal amounts in normal granulocytes. The CGM6 gene product might, therefore, represent a myeloid marker. Analyses of CGM6 protein-expressing HeLa transfectants with monoclonal antibodies strongly indicate that the CGM6 gene codes for the CEA family member NCA-95.